BACKGROUND: Reports have implied etoposide as the cause of secondary leukaemia in patients treated for germ cell cancer. PATIENTS AND METHODS: Between 1979 and 1992, 679 male patients with germ cell cancer received etoposide containing chemotherapy. RESULTS: Six of 679 patients developed acute myeloid leukaemia (relative risk 150; CI: 55-326). None of these patients had a primary mediastinal germ cell tumour and only 1 patient received previous radiotherapy. The median interval between the onset of cytotoxic treatment and the development of leukaemia was 27 months. The FAB M4 morphology was seen in 4 of 6 cases. CONCLUSION: The benefit of etoposide containing protocols outweigh the risk of leukaemia in patients with intermediate or high risk disease, however in patients with good risk disease non-etoposide containing protocols should be explored.
BACKGROUND: Reports have implied etoposide as the cause of secondary leukaemia in patients treated for germ cell cancer. PATIENTS AND METHODS: Between 1979 and 1992, 679 male patients with germ cell cancer received etoposide containing chemotherapy. RESULTS: Six of 679 patients developed acute myeloid leukaemia (relative risk 150; CI: 55-326). None of these patients had a primary mediastinal germ cell tumour and only 1 patient received previous radiotherapy. The median interval between the onset of cytotoxic treatment and the development of leukaemia was 27 months. The FAB M4 morphology was seen in 4 of 6 cases. CONCLUSION: The benefit of etoposide containing protocols outweigh the risk of leukaemia in patients with intermediate or high risk disease, however in patients with good risk disease non-etoposide containing protocols should be explored.
Authors: Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa Journal: J Natl Cancer Inst Date: 2010-06-28 Impact factor: 13.506
Authors: J Wierecky; C Kollmannsberger; I Boehlke; M Kuczyk; J Schleicher; N Schleucher; B Metzner; L Kanz; J T Hartmann; C Bokemeyer Journal: J Cancer Res Clin Oncol Date: 2004-12-31 Impact factor: 4.553
Authors: Antoine F Villa; Souleiman El Balkhi; Radia Aboura; Herve Sageot; Helene Hasni-Pichard; Marc Pocard; Dominique Elias; Nathalie Joly; Didier Payen; François Blot; Joel Poupon; Robert Garnier Journal: Ind Health Date: 2014-10-17 Impact factor: 2.179
Authors: Lindsay M Morton; Anthony J Swerdlow; Michael Schaapveld; Safaa Ramadan; David C Hodgson; John Radford; Flora E van Leeuwen Journal: EJC Suppl Date: 2014-05-29